Company Overview and News
One of the more popular strategies among investors today is to seek out “home runs.” These are lesser-known companies that have tremendous upside potential, but carry the risk of collapsing should business prospects go awry. While a balanced portfolio allows for some speculation, now is also a great time to consider S&P 500 stocks.
LMT HD EA FB UPS MA DRI FDX BBY HOG GT V AMZN CVX RTN ABBV HPQ MO
Home improvement stocks like Home Depot (NYSE:HD) and Lowes (NYSE:LOW) are on the move. The pair recently lifted to new record highs amid some serious muscle-flexing. But it’s the price pattern in Home Depot stock that is catching my eye today. Let’s dissect its chart and discuss a potential trade idea.
The past year has been tremendous for e-commerce giant Amazon (AMZN - Free Report) . The stock has gained a massive 96.8%, way ahead of the 15.8% rise of the S&P 500 Index. Online media giant Netflix (NFLX - Free Report) has surged 88.7%. Leading pizza delivery company, Domino’s Pizza (DPZ - Free Report) has risen 40.1% over the past year. On the contrary, retail drug store industry majors, Rite Aid (RAD - Free Report) and Walgreens Boots Alliance (WBA - Free Report) have witnessed a steep decline of 52.
HD TGT TXN RAD MDPEB WBA NFLX MDP
The obituaries that were written for the retail sector may have been premature. The shares of several major chain stores, including Home Depot (NYSE:HD) stock, have gained significant ground during the latest rally. Home Depot stock is now at an all-time high. But HD stock still has many positive catalysts. so it’s not too late to buy the shares.
LOW HD TGT WMT
Florence, now a tropical depression, made landfall in North Carolina on Friday, bringing with it destruction and calamity, the cost of which could top $170 billion, according to analytics firm CoreLogic. If so, that would make it the costliest storm ever to hit the U.S. To date, 2005’s Hurricane Katrina holds the top spot, costing an estimated $160 billion, followed by last year’s Harvey ($125 billion) and Maria ($90 billion).
LOW HD GS
Home improvement sales will rise due to increasing sales in the areas affected by storm Florence, according to Jefferies.
Walt Disney's three-year forward CAGR of 12% is increasing and will give you good growth with the streaming of ESPN and Disney content like Star Wars, The Avengers, and Frozen.
HD AMT ADPVV JNJ ADP LB EOS DIS
Chicago, IL – September 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include United States Gasoline ETF (UGA - Free Report) , Invesco Dynamic Building & Construction ETF (PKB - Free Report) , Materials Select Sector SPDR Fund (XLB - Free Report) and AdvisorShares VICE ETF (ACT - Free Report) .
HD PM VGR GNRC BECN BATS 4162 HRI HTZ CAR MO
“We are all in the gutter, but some of us are looking at the stars”. The quote is from the 19th century Irish poet and playwright Oscar Wilde, but it could have been uttered by Wall Street analysts who follow Lumber Liquidators (LL). Optimism certainly reigns among those analysts about a company that has not turned an annual profit since 2014. Average 2019 earnings for the flooring retailer is projected to be $0.
HD FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT
On a busy week of economic data and hurricane-related disruptions, US equities advanced 1% while real estate equities finished roughly flat. Housing-related categories await the impact of Hurricane Florence.
HD BAMGF DRE EQIX LEN CG CLGX MDC BAMKF BAM
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to HD / Home Depot, Inc. (The) on message board site Silicon Investor.
as of ET